APA (7th ed.) Citation

Fontes, M. S. C., Dingemanse, J., Halabi, A., Tomaszewska-Kiecana, M., & Sidharta, P. N. (2022). Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment. Scientific reports, 12(1), 19067-7. https://doi.org/10.1038/s41598-022-22470-z

Chicago Style (17th ed.) Citation

Fontes, Magda S. C., Jasper Dingemanse, Atef Halabi, Monika Tomaszewska-Kiecana, and Patricia N. Sidharta. "Single-dose Pharmacokinetics, Safety, and Tolerability of the Dual Endothelin Receptor Antagonist Aprocitentan in Subjects with Moderate Hepatic Impairment." Scientific Reports 12, no. 1 (2022): 19067-7. https://doi.org/10.1038/s41598-022-22470-z.

MLA (9th ed.) Citation

Fontes, Magda S. C., et al. "Single-dose Pharmacokinetics, Safety, and Tolerability of the Dual Endothelin Receptor Antagonist Aprocitentan in Subjects with Moderate Hepatic Impairment." Scientific Reports, vol. 12, no. 1, 2022, pp. 19067-7, https://doi.org/10.1038/s41598-022-22470-z.